* Alfacell Corp., of Bloomfield, N.J., said that its common stock hasbeen accepted for listing on the NASDAQ SmallCap MarketSecurities system, with trading expected to commence within oneweek.

* IntroBiotics Pharmaceuticals Inc., of Sunnyvale, Calif., said itcompleted preclinical studies for IB-367, a novel antimicrobial thecompany is developing as a potential treatment for oral mucositis, adose-limiting complication of chemotherapy and radiation therapy.IB-367 is one of the company's protegrin family of compounds,proprietary antimicrobial peptides that exhibit rapid killing activityagainst a broad spectrum of disease organisms. The companyanticipates filing an investigational new drug application in the firstquarter of 1997.

* MDL Information Systems Inc., of San Leandro, Calif., has signedan exclusive agreement with Molecular Informatics Inc., of Santa Fe,N.M., to market bioinformatics software and data bases designed tospeed development of the next generation of pharmaceuticals,agricultural control agents and gene-based therapies.

* NABI, of Boca Raton, Fla., said it has been awarded a $57 millionthree-year plasma supply contract by Korea Green Cross Corp. basedin Seoul. NABI will supply Korea Green Cross with at least $19million of plasma per year from 1997 through 1999 at a fixed pricethe first year and with an option to adjust pricing to reflect the marketduring the second and third years of the agreement, subject to certainminimums. Previously, NABI has supplied Korea Green Cross withplasma on a spot-sale basis.

* Quintiles Transnational Corp., of Triangle Park, N.C., hascompleted the acquisition of BRI International Inc., Arlington, Va..BRI is an international contract research organization withapproximately 500 employees. Quintiles has approximately 3,400employees in 52 operating units in 20 countries.

* The University of Massachusetts Amherst and Advanced CellTechnology Inc., of Waterville, Maine, have formed a new researchand licensing agreement, which includes a $578,000 two-year grantto the university for research on the development of new technologyfor the genetic modification of tissue and organs from cows, chickensand pigs.

(c) 1997 American Health Consultants. All rights reserved.

No Comments